Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers

Inclusion Criteria: * Female patients age ≥ 18 years. * Life expectancy of \>3 months. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. * Histologically confirmed metastatic advanced gynecological cancer. All epithelial subtypes are permitted. Patients receiving standard of care oncological treatment (i.e. chemotherapy and/or radiation) will be included. * Patient is able to understand and is willing to sign a written informed consent document prior to registration/enrollment on to study. * Patient is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. * Patients of childbearing potential (as assessed by their local Investigator) and their partners who are sexually active must agree to the use of 2 highly effective forms of contraception throughout the period of study treatment and for 12 months after last dose of study drug. * Baseline corrected QT (QTc) interval prolongation \< 470 milliseconds. * Within 8 days of the proposed enrollment patients must have adequate organ function. Exclusion Criteria: * Patient is a candidate for therapy with curative intent. * Patient has a contraindication to PET/CT imaging, including, but not limited to, phobias associated with imaging (e.g. claustrophobia) and those who cannot lie still in the supine position for at least 20 minutes. * Patients receiving nuclear medicine scans with other radiopharmaceutical agents (ex: 18F-FDG or other) during the study…